Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
TWST Twist Bioscience Corporation daily Stock Chart
TWST [NASD]
Twist Bioscience Corporation
Healthcare | Medical Laboratories & Research | USA
financial highlights | statements
Index- P/E- EPS (ttm)-2.57 Insider Own22.20% Shs Outstand28.97M Perf Week11.96%
Market Cap827.09M Forward P/E- EPS next Y- Insider Trans- Shs Float20.70M Perf Month80.35%
Income-68.40M PEG- EPS next Q- Inst Own0.01% Short Float0.25% Perf Quarter-
Sales20.50M P/S40.35 EPS this Y-34.50% Inst Trans- Short Ratio0.20 Perf Half Y-
Book/sh-56.69 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh3.19 P/C8.94 EPS next 5Y- ROE- 52W Range12.38 - 34.46 Perf YTD103.93%
Dividend- P/FCF- EPS past 5Y- ROI47.60% 52W High-15.99% Beta-
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin-46.10% 52W Low133.84% ATR3.90
Employees221 Current Ratio5.70 Sales Q/Q103.10% Oper. Margin- RSI (14)- Volatility20.04% 17.96%
OptionableNo Debt/Eq- EPS Q/Q-23.10% Profit Margin- Rel Volume0.66 Prev Close28.55
ShortableYes LT Debt/Eq- EarningsDec 19 AMC Payout- Avg Volume254.39K Price28.95
Recom- SMA2012.98% SMA5025.30% SMA20025.30% Volume11,636 Change1.40%
Nov-26-18Initiated JP Morgan Neutral $27
Dec-05-18 08:00AM  Twist Bioscience to Report Fiscal 2018 Fourth Quarter and Full Year Financial Results on Wednesday, December 19, 2018 Business Wire
Nov-27-18 08:00AM  Twist Bioscience to Present at the Evercore ISI HealthCONx Conference Business Wire -9.29%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
08:00AM  Twist Bioscience Appoints Experienced Technology Executive Jan Johannessen to Board of Directors Business Wire
Oct-31-18 02:45PM  Twist Bioscience Corporation Announces Pricing of Initial Public Offering Business Wire
Oct-28-18 10:53AM  IPO Outlook For The Week: Banks And Biotechs Benzinga
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company was founded in 2013 and is headquartered in San Francisco, California.
open in yahoo | open in reuters | open in google